|
1
|
Rassy E, Assi T and Pavlidis N: Exploring
the biological hallmarks of cancer of unknown primary: Where do we
stand today? Br J Cancesr. 122:1124–1132. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sacks D, Baxter B, Campbell BCV, Carpenter
JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA,
et al: Multisociety consensus quality improvement revised consensus
statement for endovascular therapy of acute ischemic stroke. Int J
Stroke. 13:612–632. 2018.PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavlidis N and Pentheroudakis G: Cancer of
unknown primary site. Lancet. 379:1428–1435. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chorost MI, Lee MC, Yeoh CB, Molina M and
Ghosh BC: Unknown primary. J Surg Oncol. 87:191–203. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bahrami A, Truong LD and Ro JY:
Undifferentiated tumor: True identity by immunohistochemistry. Arch
Pathol Lab Med. 132:326–348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greco FA and Pavlidis N: Treatment for
patients with unknown primary carcinoma and unfavorable prognostic
factors. Semin Oncol. 36:65–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang BL and Lim YS: Regarding the
manuscript of Huang et al. published in Acta Histochemica
(doi:10.1016/j.acthis.2010.06.003). Acta Histochem. 113:677–678.
675–676. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van de Wouw AJ, Janssen-Heijnen ML,
Coebergh JW and Hillen HF: Epidemiology of unknown primary tumours;
Incidence and population-based survival of 1285 patients in
Southeast Netherlands, 1984–1992. Eur J Cancer. 38:409–413. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Strojan P, Ferlito A, Medina JE, Woolgar
JA, Rinaldo A, Robbins KT, Fagan JJ, Mendenhall WM, Paleri V,
Silver CE, et al: Contemporary management of lymph node metastases
from an unknown primary to the neck: I. A review of diagnostic
approaches. Head Neck. 35:123–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boussios S, Rassy E, Samartzis E,
Moschetta M, Sheriff M, Pérez-Fidalgo JA and Pavlidis N: Melanoma
of unknown primary: New perspectives for an old story. Crit Rev
Oncol Hematol. 158:1032082021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Conway AM, Mitchell C, Kilgour E, Brady G,
Dive C and Cook N: Molecular characterisation and liquid biomarkers
in carcinoma of unknown primary (CUP): Taking the ‘U’ out of ‘CUP’.
Br J Cancer. 120:141–153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Keller LM, Galloway TJ, Holdbrook T, Ruth
K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B and
Ridge JA: p16 status, pathologic and clinical characteristics,
biomolecular signature, and long-term outcomes in head and neck
squamous cell carcinomas of unknown primary. Head Neck.
36:1677–1684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Losa F, Soler G, Casado A, Estival A,
Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J and Seguí
MÁ: SEOM clinical guideline on unknown primary cancer (2017). Clin
Transl Oncol. 20:89–96. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tomuleasa C, Zaharie F, Muresan MS, Pop L,
Fekete Z, Dima D, Frinc I, Trifa A, Berce C, Jurj A, et al: How to
diagnose and treat a cancer of unknown primary site. J
Gastrointestin Liver Dis. 26:69–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moran S, Martinez-Cardús A, Boussios S and
Esteller M: Precision medicine based on epigenomics: The paradigm
of carcinoma of unknown primary. Nat Rev Clin Oncol. 14:682–694.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rassy E and Pavlidis N: The diagnostic
challenges of patients with carcinoma of unknown primary. Expert
Rev Anticancer Ther. 20:775–783. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Erlander MG, Ma XJ, Kesty NC, Bao L,
Salunga R and Schnabel CA: Performance and clinical evaluation of
the 92-gene real-time PCR assay for tumor classification. J Mol
Diagn. 13:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pillai R, Deeter R, Rigl CT, Nystrom JS,
Miller MH, Buturovic L and Henner WD: Validation and
reproducibility of a microarray-based gene expression test for
tumor identification in formalin-fixed, paraffin-embedded
specimens. J Mol Diagn. 13:48–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Varadhachary GR, Spector Y, Abbruzzese JL,
Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S,
Macinskas J, et al: Prospective gene signature study using microRNA
to identify the tissue of origin in patients with carcinoma of
unknown primary. Clin Cancer Res. 17:4063–4070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hainsworth JD, Rubin MS, Spigel DR, Boccia
RV, Raby S, Quinn R and Greco FA: Molecular gene expression
profiling to predict the tissue of origin and direct site-specific
therapy in patients with carcinoma of unknown primary site: A
prospective trial of the Sarah Cannon research institute. J Clin
Oncol. 31:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boorjian S: Commentary on ‘Predicted
plasma 25-hydroxyvitamin D and risk of renal cell cancer.’ Joh HK,
Giovannucci EL, Bertrand KA, Lim S, Cho E, Department of medicine,
seoul national university college of medicine, Seoul, South Korea.
J Natl Cancer Inst. 2013.105((10)): 726–32, [Epub 2013 Apr 8]. doi:
10.1093/jnci/djt082. Urol Oncol. 32:933–934. 2014.
|
|
23
|
Greco FA: Cancer of unknown primary or
unrecognized adnexal skin primary carcinoma? Limitations of gene
expression profiling diagnosis. J Clin Oncol. 31:14792013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Daud AI: Removing the unknown from the
carcinoma of unknown primary. J Clin Oncol. 31:174–175. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El Rassy E, Khaled H and Pavlidis N:
Liquid biopsy: A new diagnostic, predictive and prognostic window
in cancers of unknown primary. Eur J Cancer. 105:28–32. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thiele JA, Bethel K, Králíčková M and Kuhn
P: Circulating tumor cells: Fluid surrogates of solid tumors. Annu
Rev Pathol. 12:419–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Economopoulou P, Mountzios G, Pavlidis N
and Pentheroudakis G: Cancer of unknown primary origin in the
genomic era: Elucidating the dark box of cancer. Cancer Treat Rev.
41:598–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rassy E, Labaki C, Chebel R, Boussios S,
Smith-Gagen J, Greco FA and Pavlidis N: Systematic review of the
CUP trials characteristics and perspectives for next-generation
studies. Cancer Treat Rev. 107:1024072022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maghami E, Ismaila N, Alvarez A, Chernock
R, Duvvuri U, Geiger J, Gross N, Haughey B, Paul D, Rodriguez C, et
al: Diagnosis and management of squamous cell carcinoma of unknown
primary in the head and neck: ASCO guideline. J Clin Oncol.
38:2570–2596. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lynch HT, Slostad B and Silberstein P:
Familial carcinoma of unknown primary. JAMA Oncol. 2:346–347. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hainsworth JD and Fizazi K: Treatment for
patients with unknown primary cancer and favorable prognostic
factors. Semin Oncol. 36:44–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rassy E, Parent P, Lefort F, Boussios S,
Baciarello G and Pavlidis N: New rising entities in cancer of
unknown primary: Is there a real therapeutic benefit? Crit Rev
Oncol Hematol. 147:1028822020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bochtler T, Löffler H and Krämer A:
Diagnosis and management of metastatic neoplasms with unknown
primary. Semin Diagn Pathol. 35:199–206. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oldenburg J, Aparicio J, Beyer J,
Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M,
de Wit R, Fosså SD, et al: Personalizing, not patronizing: The case
for patient autonomy by unbiased presentation of management options
in stage I testicular cancer. Ann Oncol. 26:833–838. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Briasoulis E, Kalofonos H, Bafaloukos D,
Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C,
Kosmidis P and Pavlidis N: Carboplatin plus paclitaxel in unknown
primary carcinoma: A phase II hellenic cooperative oncology group
study. J Clin Oncol. 18:3101–3107. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Galloway TJ and Ridge JA: Management of
squamous cancer metastatic to cervical nodes with an unknown
primary site. J Clin Oncol. 33:3328–3337. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Balaker AE, Abemayor E, Elashoff D and
John MA: Cancer of unknown primary: Does treatment modality make a
difference? Laryngoscope. 122:1279–1282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Olivier T, Fernandez E, Labidi-Galy I,
Dietrich PY, Rodriguez-Bravo V, Baciarello G, Fizazi K and
Patrikidou A: Redefining cancer of unknown primary: Is precision
medicine really shifting the paradigm? Cancer Treat Rev.
97:1022042021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chebly A, Yammine T, Boussios S, Pavlidis
N and Rassy E: Chromosomal instability in cancers of unknown
primary. Eur J Cancer. 172:323–325. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hainsworth JD, Spigel DR, Thompson DS,
Murphy PB, Lane CM, Waterhouse DM, Naot Y and Greco FA:
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line
treatment of patients with carcinoma of unknown primary site.
Oncologist. 14:1189–1197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hainsworth JD, Spigel DR, Farley C,
Thompson DS, Shipley DL and Greco FA; Minnie Pearl Cancer Research
Network, : Phase II trial of bevacizumab and erlotinib in
carcinomas of unknown primary site: The minnie pearl cancer
research network. J Clin Oncol. 25:1747–1752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kourie HR, Awada G and Awada AH: Unknown
primary tumors: Is there a future therapeutic role for immune
checkpoint inhibitors? Future Oncol. 12:429–431. 2016. View Article : Google Scholar : PubMed/NCBI
|
